Targeting c-MYC: a potential non-hormonal therapeutic approach for endometriosis treatment

Warren B Nothnick, Sachith Polpitiya Arachchige, Paige Minchella, Edward B Stephens, Amanda Graham
Frontiers in cell and developmental biology · 2023 · vol. 11 , pp. 1225055 · doi:10.3389/fcell.2023.1225055 · PMID:38078012 · W4388941238
article OA: gold CC0
🔓 Open OA copy View on OpenAlex View on PubMed View at publisher
⚙ AI-generated summary by claude@2026-06, 2026-06-09 ⓘ

This paper explores targeting elevated c-MYC in endometriosis with Omomyc, presenting in vitro data that Omomyc reduces endometriotic cell proliferation and viability.

One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works

⚙ AI-generated deep summary by claude@2026-06, 2026-06-10 ⓘ

This perspective article discusses endometriosis and compares its similarities to endometrial cancer to identify potential non-hormonal therapeutic targets, focusing on the transcription factor c-MYC. It notes that c-MYC is elevated in eutopic endometrium and endometriotic lesions, and that both diseases share estrogen-linked progression and cancer-like features such as EMT; as preliminary evidence, it describes in vitro findings that targeting c-MYC with Omomyc reduces endometriotic cell proliferation and viability. A key limitation is that the paper provides only preliminary, largely comparative and in vitro data rather than clinical or in vivo validation. This paper is centrally about endometriosis — it argues for c-MYC (via Omomyc) as a potential non-hormonal therapeutic target for endometriosis treatment.

Read from the paper's body, not the abstract. Not a substitute for reading the paper. No clinical advice. How this works

Abstract

Endometriosis is a benign gynecological disease in which eutopic endometrial tissue composed of glands and stroma grow within the pelvic cavity. The disease affects females of reproductive age and is characterized by pelvic pain, infertility and reduced quality of life. The majority of pharmacologic treatment modalities for endometriosis focus on suppression of estradiol production and/or action; an approach associated with adverse side effects. c-MYC is elevated in eutopic endometrium and endometriotic lesion tissue in patients with endometriosis and the disease shares many similar pathological characteristics with that of endometrial carcinoma. While targeting of c-MYC with Omomyc has recently gained substantial interest in the field of cancer research, there has been no recent attempt to evaluate the potential utility in targeting c-MYC for endometriosis treatment. The following perspective article compares the similarities between endometriosis and endometrial cancer and presents preliminary data suggesting that targeting c-MYC with Omomyc reduces endometriotic cell proliferation and viability in vitro . Future application of targeting c-MYC in endometriosis treatment and potential pros and cons are then discussed.

My notes (saved in your browser only)

Condition tags

endometriosisinfertility

Citation neighborhood

Papers in the corpus that this work cites (lower rings, blue) and that cite this one (upper rings, green). Dot size scales with the paper's in-corpus citation count — bigger dot = more influential within the endo/adeno field. Click a dot to open that paper. [ expand to 2 hops ] — adds papers reached through this work's immediate citers/citees. Heavier; up to 60 extra dots.

References (75)

Source provenance

europepmc
last seen: 2026-06-04T01:30:01.192114+00:00
openalex
last seen: 2026-06-10T17:14:06.276822+00:00
pubmed
last seen: 2026-06-04T00:33:16.146570+00:00
License: CC0 · commercial use OK